CLAIMS

1. ~~Use of a~~A composition ~~in the manufacture of a medicament~~ for use in treating cancer, wherein the composition comprises an antibody that binds to CD47 or an antigen-binding fragment thereof comprising a variable heavy chain (VH) ~~region and a variable light chain (VL) region combination selected from the group consisting of:~~CDR1 comprising SEQ ID NO: 50, a VH CDR2 comprising SEQ ID NO: 72, a VH CDR3 sequence comprising SEQ ID NO: 52, a variable light chain (VL) CDR1 comprising SEQ ID NO: 53, a VL CDR2 comprising SEQ ID NO: 71, and a VL CDR3 comprising SEQ ID NO: 55, wherein the composition is to be administered in combination with rituximab, wherein the administration of rituximab to the subject results in B cell depletion and a reduction in immune response in the subject to the antibody that binds to CD47 or an antigen-binding fragment thereof.

2. The composition for use of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a VH ~~region~~ comprising a sequence ~~having 2-12 amino acid modifications in the framework region~~selected from the group consisting of SEQ ID ~~NO: 7,~~NOs: 6 and 11.

3. The composition for use of claim 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises a VL ~~region~~ comprising a sequence ~~having 1-11 amino acid modifications in the framework region~~selected from the group consisting of SEQ ID ~~NO: 33; a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7,~~NOs: 42 and ~~a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 34;~~46.

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 35;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 36;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 39;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 43;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 42;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 43;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 44;~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 47; and~~

~~a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 28, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 35.~~

~~2~~

4. The composition for use ~~according~~of any one of claims 1 to ~~claim 1~~3, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.

~~3~~5. The composition for use ~~according to~~of any one of claims 1 to ~~2~~3, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.

~~4~~6. The composition for use ~~according to~~of any one of claims 1 to ~~3~~5, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

~~5~~7. The composition for use ~~according to~~of any one of claims 1 to ~~4~~6, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject at a dose of 0.3, 1, 2, 4, 8, 15, or 20 mg/kg.

~~6~~8. The composition for use ~~according to~~of any one of claims 1 to ~~5~~7, wherein the rituximab is to be administered to the subject at a dose of 300, 325, 350, 375, 400, 425, 450, or 500 mg/m^2.

~~7.~~

9. The composition for use ~~according to~~of any one of claims 1 to ~~6~~8, wherein the composition further comprises another anti-cancer agent.

~~8~~10. The composition for use ~~according to~~of any one of claims 1 to ~~7~~9, wherein the cancer is a hematological cancer.

11.

~~9.~~ The composition for use ~~according to~~of claim ~~8~~10, wherein the hematological cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia (AML).

12.

~~10.~~ The composition for use ~~according~~of any one of claims 1 to ~~claim 9~~11, wherein the ~~hematological cancer~~composition is ~~non-Hodgkin's lymphoma.~~

~~11. The use according~~not to ~~claim 10, wherein~~ be administered with a proteosome inhibitor to the ~~non-Hodgkin's lymphoma is CD20 positive~~subject.

~~12.~~

13. The composition for use ~~according to~~of claim ~~10~~12, wherein the ~~non-Hodgkin's lymphoma is relapsed or refractory.~~

composition is not

~~13. The use according~~ to ~~claim 10, wherein~~ be administered with bortezomib to the subject ~~has previously been treated with rituximab~~.

14.

~~14.~~ The composition for use ~~according to~~of any one of claims 1 to ~~9~~13, wherein the composition ~~does not comprise a proteosome inhibitor.~~

~~15. The~~for use ~~according~~is not to ~~claim 14, wherein the proteosome inhibitor is bortezomib.~~

~~16. The use according to any one of claims 1 to 15, wherein the composition does not comprise~~be administered with methotrexate~~.~~ to the subject.